Yahoo · Sep 4, 2026
Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NYSE · CRL
Charles River Laboratories International, Inc.
Healthcare · Medical - Diagnostics & Research
$278.35
Down-$5.86 (-2.11%)
Updated Sep 10, 2026, 3:15 PM
SID Score
6.5/10
Composite research score
Smart Money
62/100
Neutral
- Market cap
- 9.57B
- P/E ratio
- -137.99
- Dividend yield
- 0.00%
- 52-week range
- $146.20 – $303.31
- Volume
- 789.22K
- Avg. volume
- 1.03M
Price performance
CRL price history
1M range · 0 trading sessions · Daily adjusted prices
CRL does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest CRL news
The latest Smart Investors Daily articles mentioning CRL.
Stock researchCompany · Overview
CRL research
Overview
Company profile and research snapshot.
Company profile
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $191.50
- Implied upside
- —
- Analysts
- 22
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 10, 2026 | TD Cowen | Buy | — |
| Aug 7, 2026 | Morgan Stanley | Overweight | — |
| Aug 6, 2026 | JP Morgan | Overweight | — |
| Aug 6, 2026 | RBC Capital | Outperform | — |
| Aug 6, 2026 | Evercore ISI Group | Outperform | — |
News briefing
No generated briefing is available yet.
Fintel · Aug 28, 2026
Charles River Laboratories International (CRL) Price Target Increased by 17.31% to 274.25
Yahoo · Aug 27, 2026
Animal Testing and Non-Animal Alternative Testing Market Outlook 2025-2035 - Featuring Profiles of Charles River Laboratories, Labcorp, and Eurofins Scientific
Opportunities center on non-animal, pharma and regulatory testing, driven by organ-on-chip, organoids, AI biosimulation, genomics and in vitro toxicity platforms.Dublin, Aug. 27, 2026 (GLOBE NEWSWIRE) -- The "Animal Testing and Non-Animal Alternative Testing Global Market Opportunities and Strategies to 2035" has been added to ResearchAndMarkets.com's offering. The latest animal testing and non-animal alternative testing market report provides a comprehensive analysis of industry performance fro
Yahoo · Aug 26, 2026
Is Wall Street Bullish or Bearish on Charles River Laboratories Stock?
Charles River Laboratories has significantly outperformed the market, while strong guidance and a bullish analyst outlook support continued optimism.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
